Dostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancer

FDA has approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) for adults with advanced renal cell carcinoma with a clear cell component following a programmed death receptor-1 or programmed death-ligand 1 inhibitor.

FDA has granted Priority Review for IMFINZI (durvalumab) in combination with enfortumab vedotin for the treatment of patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.